Trevena announces pricing of public offering
|
05 Dec 2014
|
|
Trevena, Inc. a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of USD 4 per share. The gross proceeds to Trevena from this offering are expected to be approximately USD 45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trevena. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock from Trevena at the public offering price. The offering is expected to close on December 10, 2014, subject to customary closing conditions. Barclays Capital Inc., Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers. |
| Source: Dion Global Type: IPO Related |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback